Target Molecules and Delivery Vehicles for Anti-HIV Drugs In vitro and In vivo

Author(s): Azam Bolhassani*

Journal Name: Current Pharmaceutical Design

Volume 24 , Issue 29 , 2018

Become EABM
Become Reviewer
Call for Editor


Acquired Immune Deficiency Syndrome (AIDS) is the most serious stage of Human Immunodeficiency Virus (HIV) infection. The combinatorial Anti-Retroviral Therapy (cART) is widely used in suppressing HIV-1 infection and enhancing life span of infected patients to a significant level. However, delivery of therapeutic molecules is still a major challenge in vivo. The studies showed that the anti-HIV drugs delivered via nanocarriers could be selectively accumulated in infected cells accompanied by low side effects. On the other hand, HIV-1 infection kinetics is different in macrophages and T-cells suggesting various effects of antiretroviral drugs against HIV-1 in these target cells. Current anti-HIV therapeutic studies have focused on developing drug delivery systems targeted specifically to HIV-infected host cells. Indeed, the drug targeting can significantly lead to reduce in drug toxicity, drug dose, and increase in treatment efficacy through localizing its pharmacological activity to the site of interest. This review describes development of novel drug targeting systems used in suppressing the transmission and treatment of HIV infections.

Keywords: Human immunodeficiency virus, therapeutics, drug delivery systems, adverse effects, acquired immune deficiency syndrome (AIDS), nano-carriers.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2018
Published on: 08 December, 2018
Page: [3393 - 3401]
Pages: 9
DOI: 10.2174/1381612824666180608124549
Price: $65

Article Metrics

PDF: 26